![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences Appoints Craig W. Carlson as Chief Financial Officer
March 11, 2010 08:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences to Present at the 12th Annual BIO CEO & Investor Conference
February 01, 2010 07:30 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 1, 2010 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences Appoints Howard Furst, M.D., M.B.A., to Board of Directors
December 16, 2009 07:00 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences Announces Positive Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia at 51st American Society of Hematology Annual Meeting
December 07, 2009 11:01 ET
|
Talon Therapeutics, Inc.
--36% Overall Response Rate and 21% Complete Remission Rate--
--Median Overall Survival of 7.3 Months in Complete Responders--
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2009 (GLOBE NEWSWIRE)...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences Completes Enrollment in Pivotal Phase 2 rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia
December 02, 2009 07:00 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 2, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that it...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences to Present Data From Pivotal rALLy Clinical Trial of Marqibo(R) in Acute Lymphoblastic Leukemia
December 01, 2009 07:00 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 1, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences to Present at the 21st Annual Piper Jaffray Healthcare Conference
November 24, 2009 16:05 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences Announces Third Quarter 2009 Results
November 13, 2009 07:05 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB) announced today financial results for the three and nine months ended September 30, 2009.
"Highlights of...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences to Present at the 8th Annual BIO Investor Forum
October 22, 2009 07:05 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
![Talon Therapeutics, Inc. Logo](/news-release/logo/214358/0/214358.jpg?lastModified=12%2F09%2F2016%2022%3A40%3A02&size=2)
Hana Biosciences Completes $12.4 Million Private Placement
October 08, 2009 19:33 ET
|
Talon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB) announced today that it has completed its previously disclosed private placement of units of its securities...